REG - Reckitt Benckiser Gp - EMTN Programme: Publication of Final Terms

Reckitt BenckiserAnnouncement

08/09/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH4265Ya&default-theme=true

RNS Number : 4265Y  Reckitt Benckiser Group PLC  08 September 2025

8 September 2025

 

RECKITT BENCKISER GROUP PLC

EMTN Programme: Publication of Final Terms

Reckitt Benckiser Group plc (the "Company"), together with Reckitt Benckiser
Treasury Services plc (the "Issuer"), announce that on 1 September 2025 they
successfully launched and priced the following notes under the GBP
10,000,000,000 Euro Medium Term Note Programme of the Issuer:

-     EUR 700,000,000 2.625% Fixed Rate Senior Notes due 10 September
2028;

-     GBP 250,000,000 4.875% Fixed Rate Senior Notes due 10 September
2031; and

-     EUR 650,000,000 3.500% Fixed Rate Senior Notes due 10 September
2034,

(together the "Notes"), each issued by the Issuer and guaranteed by the
Company. The Notes are expected to be issued on 10 September 2025.

The Final Terms dated 8 September 2025 relating to the Notes are available for
viewing. To view the full documents, please paste the following URL into the
address bar of the browser:

 https://reckitt.com/investors/your-shareholding/emtn-programme-documents/
(https://reckitt.com/investors/your-shareholding/emtn-programme-documents/)

A copy of the Final Terms has been submitted to the National Storage Mechanism
and will shortly be available for inspection at:

 https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

The Final Terms should be read and construed in conjunction with the Base
Prospectus dated 29 August 2025.

 

Nick Ashworth
                                                            +44
(0) 7408 812350

Investor Relations

 

Catheryn O'Rourke
                                                      +44
(0) 1753 217 800

General Counsel & Company Secretary

 

About Reckitt*:

 

We make the products people trust to care for the ones they love. We are home
to some of the world's best-loved consumer health and hygiene brands,
including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen,
Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By
creating innovative, science-backed solutions, we support people every day to
live healthier lives.

 

Reckitt exists to protect, heal and nurture in the pursuit of a cleaner,
healthier world. This commitment goes beyond the products we make. Through our
actions, we expand access to healthcare, education and economic opportunities.
We support the planet by reducing waste, conserving resources and driving
sustainable innovation.

 

We believe good health starts at home. With every action we take, we strive to
make our consumers' lives easier, cleaner and healthier, to strengthen
communities and to create a more sustainable future.

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

This announcement does not constitute or form part of an offer to sell or the
solicitation of an offer to subscribe for or otherwise acquire any securities.

The securities referred to herein and the guarantee thereof have not been and
will not be registered under the U.S. Securities Act of 1933, as amended (the
"Securities Act"), or with any securities regulatory authority of any State or
other jurisdiction of the United States, and are subject to Unites States tax
law requirements. Subject to certain exceptions, the securities referred to
herein may not be offered, sold or delivered in the United States (as defined
in Regulation S under the Securities Act) or to, or for the account or benefit
of, U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as
amended, and regulations thereunder). The Base Prospectus may not be accessed
from, or transmitted in or into, the United States. Accordingly, these
securities may not be offered, sold or delivered in the United States.

Please note that the information contained in the Final Terms may be addressed
to and/or targeted at persons who are residents of particular countries
(specified in the Final Terms and the Base Prospectus) only and is not
intended for use and should not be relied upon by any person outside these
countries and/or to whom the offer contained in the Final Terms is not
addressed. Prior to relying on the information contained in the Final Terms
you must ascertain from the Base Prospectus whether or not you are part of the
intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above
requirements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFTSSUFSAEISESU